Filing Flows › Aktis Oncology (AKTS) › Q2 2026 › vs Q1 2026
Aktis Oncology (AKTS) Q2 2026 vs Q1 2026 (quarter over quarter)
Aktis Oncology's revenue rose $157K (+5%) from $3.2M in Q1 2026 to $3.4M in Q2 2026.
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3.4M | $3.2M | $157K | +5% |
| Other income, net | $4.8M | $4.4M | $374K | +9% |
| Net loss | $24.1M | $18.3M | $5.8M | +32% |
| Costs & expenses | $32.3M | $25.9M | $6.3M | +24% |
| Operating costs | $32.3M | $25.9M | $6.3M | +24% |
| Research & development | $25.3M | $20.0M | $5.2M | +26% |
| General & admin | $7.0M | $5.9M | $1.1M | +19% |
| Operating cash sources | $24.7M | $27.9M | −$3.2M | -12% |
| Depreciation & amortization | $879K | $652K | $227K | +35% |
| Share-based compensation | $3.2M | $3.0M | $200K | +7% |
| Cash used in operations | $20.6M | $24.2M | −$3.7M | -15% |
| Net loss absorbed | $24.1M | $18.3M | $5.8M | +32% |
| Working capital & other | $544K | $9.6M | −$9.0M | -94% |
Questions
How much did Aktis Oncology's revenue grow quarter over quarter in Q2 2026?
Aktis Oncology's revenue rose $157K (+5%) from $3.2M in Q1 2026 to $3.4M in Q2 2026.